Analysis of patients with breast cancer showed that compared with low EphA2 expression, high EphA2 expression is significantly associated with longer survival times in patients with estrogen receptor-positive HER2-negative breast cancers with low RNF5 expression, who accounts for approximately two-thirds of the breast cancer cohort. This evidence concerns the gene ESR1 and breast carcinoma.